Monopar Therapeutics (NASDAQ:MNPR) Receives Overweight Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report published on Wednesday morning, MarketBeat Ratings reports. They currently have a $76.00 target price on the stock.

Separately, HC Wainwright boosted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd.

Monopar Therapeutics Price Performance

MNPR stock opened at $39.10 on Wednesday. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The business has a fifty day moving average price of $36.46 and a 200-day moving average price of $22.11. The stock has a market capitalization of $238.59 million, a P/E ratio of -19.85 and a beta of 1.18.

Institutional Trading of Monopar Therapeutics

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in Monopar Therapeutics during the fourth quarter valued at $45,000. Geode Capital Management LLC increased its position in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after acquiring an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Monopar Therapeutics during the fourth quarter valued at $2,861,000. Point72 Asset Management L.P. purchased a new stake in Monopar Therapeutics during the fourth quarter valued at $3,694,000. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics during the fourth quarter valued at $11,247,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.